{"id":"W4402558540","doi":"10.1016/j.annonc.2024.08.2251","title":"LBA13 Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR+/HER2− early breast cancer (EBC): 4-year outcomes from the NATALEE trial","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"Loxo Oncology; Sociedad Española de Oncología Médica; PharmaMar; European Society for Medical Oncology; Eisai; Seagen; G1 Therapeutics; MacroGenics; Genentech; Veracyte; Pfizer; Incyte; Mersana Therapeutics; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Mylan; AstraZeneca; Novocure; Eli Lilly and Company; National Comprehensive Cancer Network; Medac; Jazz Pharmaceuticals; Puma Biotechnology; Bristol-Myers Squibb; American Society of Clinical Oncology; Amgen; Radius Health; Daiichi Sankyo Europe; Gilead Sciences; Merck KGaA; Exelixis; Sanofi; Celgene","keywords":"Medicine; Aromatase inhibitor; Breast cancer; Internal medicine; Nonsteroidal; Adjuvant; Oncology; Aromatase; Cancer; Gynecology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002930075,0.0003365757,0.0009336075,0.0001614091,0.00005702715,0.00002806241,0.0002727947,0.000216455,0.000350461],"category_scores_gemma":[0.00006770218,0.0002096896,0.0001757034,0.0003445233,0.000412042,0.0002792987,0.000118916,0.0005224523,0.00007053876],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002584623,"about_ca_system_score_gemma":0.0007419027,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002140801,"about_ca_topic_score_gemma":0.00107385,"domain_scores_codex":[0.9976512,0.0001729053,0.0006407839,0.0005307161,0.0004971338,0.0005072959],"domain_scores_gemma":[0.9984253,0.0004706433,0.0002356402,0.0004977246,0.0002117814,0.0001589303],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.192788,0.002315374,0.4338779,0.0002278687,0.001966563,0.000708776,0.006826109,0.00008050268,0.0006261596,0.0001948659,0.009541867,0.350846],"study_design_scores_gemma":[0.09091541,0.006798746,0.8725789,0.0009481572,0.0002406582,0.00004459168,0.0007473608,0.00004051864,0.0007426236,0.0003070854,0.02621303,0.0004229533],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9828225,0.001639508,0.00001791322,0.0110251,0.001041402,0.001107512,0.0020639,0.00007509697,0.0002071169],"genre_scores_gemma":[0.9963229,0.0001224688,0.0001999216,0.002097435,0.0006431377,0.0001924937,0.0001712832,0.00006678604,0.0001836099],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.438701,"threshold_uncertainty_score":0.8550896,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03707574296529653,"score_gpt":0.3526388762594793,"score_spread":0.3155631332941828,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}